Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

SAFETY AND ACTIVITY OF TRABECTEDIN AS FIRST LINE IN ADVANCED SOFT TISSUE SARCOMA (STS) PATIENTS UNFIT TO RECEIVE STANDARD CHEMOTHERAPY: A PROSPECTIVE PHASE II STUDY WITH CLINICAL AND MOLECULAR CORRELATES

NCT02066675 is registered in ClinicalTrials.gov with Italian Sarcoma Group as lead sponsor.

NCT NCT02066675
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02066675 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
SAFETY AND ACTIVITY OF TRABECTEDIN AS FIRST LINE IN ADVANCED SOFT TISSUE SARCOMA (STS) PATIENTS UNFIT TO RECEIVE STANDARD CHEMOTHERAPY: A PROSPECTIVE PHASE II STUDY WITH CLINICAL AND MOLECULAR CORRELATES
Lead sponsor
Italian Sarcoma Group
Phase
Phase 2
Overall status
Completed
Start date
February 28, 2014
Completion date
December 31, 2016
Enrollment
24 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic and locally advanced soft tissue tumor patients unfit to receive, standard chemotherapy